Thrombosis
Conference Coverage
Ticagrelor reversal agent looks promising
NEW ORLEANS – Ticagrelor’s antiplatelet effect was squelched within 5 minutes.
Conference Coverage
Occurrence of pulmonary embolisms in hospitalized patients nearly doubled during 2004-2015
NEW ORLEANS – National Inpatient Sample data showed that during 2004-2015 hospitalized U.S. patients with a PE diagnosis jumped by 80%.
From the Journals
What does COMPASS mean for vascular surgeons?
Video
AUGUSTUS: Dual surpasses triple therapy when AFib patients have PCI or ACS
NEW ORLEANS – Dropping aspirin but keeping anticoagulation with apixaban and antiplatelet clopidogrel was effective and associated with less...
Conference Coverage
Andexanet alfa effectively reverses factor Xa inhibition
HONOLULU – The drug establishes good or excellent hemostasis in 82% of patients with acute major bleeding associated...
Conference Coverage
Eisenmenger syndrome is a minefield for unwary physicians
SNOWMASS, COLO. –
Conference Coverage
Myeloma therapies raise cardiovascular risks
WASHINGTON – The proteasome inhibitor carfilzomib increases risk for heart failure, and thalidomide analogs increase the risk for venous...
News from the FDA/CDC
FDA: Safety signal emerged with higher dose of tofacitinib in RA study
The FDA is working with Pfizer to better understand how the signal affects patients and how the drug should be used, the agency said in a...
From the Journals
ICYMI: Rivaroxaban reduces VTE incidence in ambulatory cancer patients
However, the reduction lost significance if treatment with rivaroxaban was halted.
From the Journals
Supplementary compression doesn’t improve DVT odds in critically ill
SAN DIEGO – The procedure carries few risks, aside from patient discomfort.
From the Journals
ICYMI: Andexanet alfa reduces anti–factor Xa activity from apixaban, rivaroxaban
Reductions were similar for those receiving apixaban and rivaroxaban.